Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: current status and future directions.

John H Stewart1, Perry Shen, Edward A Levine

  • 1Surgical Oncology Service, Department of General Surgery, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA.

Annals of Surgical Oncology
|September 1, 2005
PubMed
Summary

Intraperitoneal hyperthermic chemotherapy offers a promising treatment for peritoneal carcinomatosis, a uniformly fatal condition. Further research and specialized centers are key to defining its optimal role in cancer therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ASO Visual Abstract: Next-Generation Sequencing Identifies Key Targetable Mutations in the Treatment of Appendiceal Neoplasms.

Annals of surgical oncology·2026
Same author

Comparative Proteomic Profiling of Responses to Standard Systemic Treatment Regimens in Pancreatic Cancer.

Cells·2026
Same author

New Consensus Statements for Peritoneal Surface Malignancy.

Annals of surgical oncology·2026
Same author

Invited Commentary: Building Bridges: A National Mentorship Network as a Model for Surgical Education.

Journal of the American College of Surgeons·2026
Same author

From Description to Action: A Roadmap for Dismantling Cancer Disparities in Surgical Oncology.

Annals of surgical oncology·2026
Same author

Enhancing Patient Lymphocyte Response to Peritoneal Malignancies Using a Personalized Immunocompetent Microfluidic Co-Culture Platform.

bioRxiv : the preprint server for biology·2026

Area of Science:

  • Oncology
  • Surgical Oncology
  • Medical Oncology

Background:

  • Peritoneal carcinomatosis has a uniformly fatal natural history, with median survival around 6 months.
  • Intraperitoneal cytoreductive surgery and hyperthermic chemotherapy represent an aggressive alternative treatment approach.
  • Hesitancy among referring physicians, particularly medical oncologists, stems from strict selection criteria and procedural variations.

Purpose of the Study:

  • To establish a conceptual framework for understanding the role of intraperitoneal hyperthermic chemotherapy (IPHC) in treating peritoneal surface malignancy.
  • To highlight the ongoing advancements and challenges associated with IPHC in the oncological community.

Main Methods:

  • This article reviews existing literature and clinical experience regarding IPHC for peritoneal carcinomatosis.

Related Experiment Videos

  • It focuses on establishing a conceptual understanding of the procedure's application and outcomes.

    • Main Results:

    • Intraperitoneal hyperthermic chemotherapy is an evolving treatment modality for peritoneal carcinomatosis.
    • Despite challenges, the procedure demonstrates advancements in oncological treatment.

    Conclusions:

    • Advancement of specialized centers of excellence is crucial for IPHC.
    • Initiation of further Phase II trials will help define the optimal treatment strategy for peritoneal carcinomatosis.